Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice

Fig. 5

Effect of one month treatment with aliskiren on Tumor necrosis factor—alpha in STZ-induced diabetes in mice. Each value represents mean of 8 mice. Statistical analysis was carried out using one way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test. *Significantly different from Normal control at P < 0.05. #Significantly different from Diabetic control at P < 0.05

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us